Nicholas Simon is an Operating Partner in the Blackstone Life Sciences group and a member of its Investment Committee, having joined Blackstone as part of its acquisition of Clarus in December 2018. Prior to joining Blackstone, Mr. Simon was co-founder and Managing Director of Clarus since the firm's inception in 2005.

Mr. Simon has over 30 years of operating and investment experience in the healthcare sector and has led investments in biotechnology, pharmaceutical company partnerships, and medical technology. Prior to Clarus, Mr. Simon was a General Partner at MPM Capital, a healthcare venture capital firm. Prior to MPM Capital, he was with Genentech from 1989 to 2000 where he was Vice President of Business and Corporate Development. Mr. Simon is currently serving on the Board of Directors of Gritstone Oncology (NASDAQ: GRTS) and Sientra (NASDAQ:SIEN).

Mr. Simon received a BS degree in microbiology from the University of Maryland and an MBA from Loyola University. Mr. Simon is a Trustee at The J David Gladstone Institutes, a private not-for-profit research institute affiliated with the University of California, San Francisco.